German court deals blow to Sanofi over cholesterol drug
05-06-2019
Fresenius files IPR against Amgen
15-04-2019
Sergiy Palamarchuk / Shutterstock.com
Sanofi secured a win at the US Court of Appeals for the Federal Circuit yesterday, August 14, after the appeals court concluded a lower court lacked authority to invalidate claims of a patent covering a prostate cancer drug.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Sanofi, US Court of Appeals for the Federal Circuit, Fresenius, generics, Jevtana, cancer drugs, patent invalidity, big pharma
